Roche has announced restructuring plans in the wake of numerous pipeline disappointments and setbacks with existing products following its Genentech acquisition. The company plans to reduce its staffing by 6%, with layoffs and unfilled positions adding up to 4,800 jobs. Roche will also cancel some development programs, shrink others, shift 800 workers to other sites and outsource an additional 700 roles. The total number of affected positions will be 6,300. The moves are intended to provide savi...